DK174025B1 - Anvendelse af visse 2',5'-oligoadenylatanaloger til fremstilling af et lægemiddel mod retrovirusinfektioner, hidtil ukendte blandt en sådan type forbindelser, også til anvendelse ved behandling af en retrovirusinfektion, samt anvendelse af ........ - Google Patents

Anvendelse af visse 2',5'-oligoadenylatanaloger til fremstilling af et lægemiddel mod retrovirusinfektioner, hidtil ukendte blandt en sådan type forbindelser, også til anvendelse ved behandling af en retrovirusinfektion, samt anvendelse af ........ Download PDF

Info

Publication number: DK174025B1
Authority: DK; Denmark
Prior art keywords: adenylyl; deoxyadenylyl; pharmaceutically acceptable; acceptable salts; triphosphates
Prior art date: 1988-06-09

Application number

DK199002913A

Other languages

Danish (da)

English (en)

Other versions

DK291390A (da

DK291390D0 (da

Inventor

Wolfgang Pfleiderer

Robert J Suhadolnik

Original Assignee

Univ Temple

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-09

Filing date

1990-12-07

Publication date

2002-04-29

1990-12-07 Application filed by Univ Temple filed Critical Univ Temple

1990-12-07 Publication of DK291390A publication Critical patent/DK291390A/da

1990-12-07 Publication of DK291390D0 publication Critical patent/DK291390D0/da

2002-04-29 Application granted granted Critical

2002-04-29 Publication of DK174025B1 publication Critical patent/DK174025B1/da

Links

SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 title claims abstract description 21
239000003814 drug Substances 0.000 title claims abstract description 12
150000001875 compounds Chemical class 0.000 title claims description 67
238000002360 preparation method Methods 0.000 title description 23
206010038997 Retroviral infections Diseases 0.000 title description 7
229940079593 drug Drugs 0.000 title description 5
208000031886 HIV Infections Diseases 0.000 claims abstract description 12
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 7
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 7
125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 claims description 62
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 54
208000015181 infectious disease Diseases 0.000 claims description 34
239000001226 triphosphate Substances 0.000 claims description 32
241000700605 Viruses Species 0.000 claims description 31
150000003839 salts Chemical class 0.000 claims description 30
OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims description 29
235000011178 triphosphate Nutrition 0.000 claims description 29
241001430294 unidentified retrovirus Species 0.000 claims description 29
OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims description 28
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 27
229960005305 adenosine Drugs 0.000 claims description 27
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 26
-1 hydroxy , amino Chemical group 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 claims description 7
230000001684 chronic effect Effects 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
239000002773 nucleotide Substances 0.000 claims description 6
208000006454 hepatitis Diseases 0.000 claims description 5
231100000283 hepatitis Toxicity 0.000 claims description 5
125000003729 nucleotide group Chemical group 0.000 claims description 5
150000002431 hydrogen Chemical class 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
ILDPUOKUEKVHIL-QYYRPYCUSA-N (2r,3r,4s,5s)-4-amino-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol Chemical compound O[C@@H]1[C@H](N)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ILDPUOKUEKVHIL-QYYRPYCUSA-N 0.000 claims description 3
ILDPUOKUEKVHIL-UHFFFAOYSA-N 3-(1,2-epoxypropyl)-5,6-dihydro-5-hydroxy-6-methylpyran-2-one Natural products OC1C(N)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 ILDPUOKUEKVHIL-UHFFFAOYSA-N 0.000 claims description 3
XHSQDZXAVJRBMX-DDHJBXDOSA-N 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1 XHSQDZXAVJRBMX-DDHJBXDOSA-N 0.000 claims description 3
229930010555 Inosine Natural products 0.000 claims description 3
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 3
229960003786 inosine Drugs 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 claims 2
230000007547 defect Effects 0.000 abstract description 17
230000037361 pathway Effects 0.000 abstract description 13
239000000203 mixture Substances 0.000 abstract description 9
239000002777 nucleoside Substances 0.000 abstract description 8
150000003833 nucleoside derivatives Chemical group 0.000 abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 abstract description 4
DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract description 3
208000035475 disorder Diseases 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 58
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
238000000034 method Methods 0.000 description 27
239000013638 trimer Substances 0.000 description 22
210000004027 cell Anatomy 0.000 description 19
230000000694 effects Effects 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
239000000243 solution Substances 0.000 description 18
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
241000725303 Human immunodeficiency virus Species 0.000 description 15
101100170604 Mus musculus Dmap1 gene Proteins 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 15
201000006747 infectious mononucleosis Diseases 0.000 description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
239000000376 reactant Substances 0.000 description 12
102000040650 (ribonucleotides)n+m Human genes 0.000 description 11
238000001704 evaporation Methods 0.000 description 11
230000008020 evaporation Effects 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
241000282414 Homo sapiens Species 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 8
108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
230000000840 anti-viral effect Effects 0.000 description 8
230000000903 blocking effect Effects 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
238000010511 deprotection reaction Methods 0.000 description 8
239000000539 dimer Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
241000701044 Human gammaherpesvirus 4 Species 0.000 description 7
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
229910052938 sodium sulfate Inorganic materials 0.000 description 7
235000011152 sodium sulphate Nutrition 0.000 description 7
239000007787 solid Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
102100034343 Integrase Human genes 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000007788 liquid Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
241000598436 Human T-cell lymphotropic virus Species 0.000 description 5
241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 5
238000005684 Liebig rearrangement reaction Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
239000001177 diphosphate Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
150000004712 monophosphates Chemical class 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 5
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 4
JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 4
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
208000000389 T-cell leukemia Diseases 0.000 description 4
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 4
230000004913 activation Effects 0.000 description 4
230000036436 anti-hiv Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000006642 detritylation reaction Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000012636 effector Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000000605 extraction Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000010992 reflux Methods 0.000 description 4
102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 3
108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 3
IOSAAWHGJUZBOG-UHFFFAOYSA-N 3-(6-amino-9h-purin-9-yl)nonan-2-ol Chemical compound N1=CN=C2N(C(C(C)O)CCCCCC)C=NC2=C1N IOSAAWHGJUZBOG-UHFFFAOYSA-N 0.000 description 3
125000001193 5'-inosinylyl group Chemical group C=12N=C([H])N=C(O[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 3
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
108010047761 Interferon-alpha Proteins 0.000 description 3
102000006992 Interferon-alpha Human genes 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000010266 Sephadex chromatography Methods 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
230000007541 cellular toxicity Effects 0.000 description 3
235000011180 diphosphates Nutrition 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
WTLPAVBACRIHHC-VMPITWQZSA-N (ne)-n-[(4-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C\C1=CC=C([N+]([O-])=O)C=C1 WTLPAVBACRIHHC-VMPITWQZSA-N 0.000 description 2
KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 2
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
229910015900 BF3 Inorganic materials 0.000 description 2
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229950006790 adenosine phosphate Drugs 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000798 anti-retroviral effect Effects 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
238000006480 benzoylation reaction Methods 0.000 description 2
238000007068 beta-elimination reaction Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
229940126545 compound 53 Drugs 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
NLIHPCYXRYQPSD-BAJZRUMYSA-N cordycepin triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C[C@H]1O NLIHPCYXRYQPSD-BAJZRUMYSA-N 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
230000005860 defense response to virus Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000006166 lysate Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
231100000956 nontoxicity Toxicity 0.000 description 2
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000008259 solid foam Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
NYKPXRVYBOPBBI-SDBHATRESA-N (2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-pentoxyoxolan-3-ol Chemical compound CCCCCO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NYKPXRVYBOPBBI-SDBHATRESA-N 0.000 description 1
YQYHADOJHFFUCK-JRFJBVBDSA-N (2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-[tert-butyl(dimethyl)silyl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1([Si](C)(C)C(C)(C)C)O[C@H](CO)[C@@H](O)[C@H]1O YQYHADOJHFFUCK-JRFJBVBDSA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
FFFOEHXFKAPYEF-KBNQYOMWSA-N (3s,4s,5r)-2-(6-aminopurin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC=NC2=C(N)N=CN1C1O[C@H](CO)[C@@H](O)[C@@H]1O FFFOEHXFKAPYEF-KBNQYOMWSA-N 0.000 description 1
YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
IHMGDCCTWRRUDX-VMPITWQZSA-N (ne)-n-[(2-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C\C1=CC=CC=C1[N+]([O-])=O IHMGDCCTWRRUDX-VMPITWQZSA-N 0.000 description 1
NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
VWCUMTCXBIRRSG-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2-methoxybenzene Chemical compound COC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 VWCUMTCXBIRRSG-UHFFFAOYSA-N 0.000 description 1
DZMDPHNGKBEVRE-UHFFFAOYSA-N 1-chloroheptane Chemical compound CCCCCCCCl DZMDPHNGKBEVRE-UHFFFAOYSA-N 0.000 description 1
SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
102100036413 2',5'-phosphodiesterase 12 Human genes 0.000 description 1
108010035903 2'-phosphodiesterase Proteins 0.000 description 1
NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
LQRAPNDKLIWRJK-UHFFFAOYSA-N 2-[2-(1-methyl-5-nitrocyclohexa-2,4-dien-1-yl)ethoxy]imidazol-3-ium-1-carboxylic acid chloride Chemical compound [Cl-].CC1(CC(=CC=C1)[N+](=O)[O-])CCOC1=[N+](C=CN1)C(=O)O LQRAPNDKLIWRJK-UHFFFAOYSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
SFYDWLYPIXHPML-UHFFFAOYSA-N 3-nitro-1-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)N1N=C([N+]([O-])=O)N=C1 SFYDWLYPIXHPML-UHFFFAOYSA-N 0.000 description 1
JMOLIBDMMGWYOR-UHFFFAOYSA-N 4-hydroxy-1,2,3,4$l^{5}-trioxaphosphetane 4-oxide Chemical class OP1(=O)OOO1 JMOLIBDMMGWYOR-UHFFFAOYSA-N 0.000 description 1
125000004032 5'-inosinyl group Chemical group 0.000 description 1
IPRDZAMUYMOJTA-UHFFFAOYSA-N 5,6-dichloro-1h-benzimidazole Chemical compound C1=C(Cl)C(Cl)=CC2=C1NC=N2 IPRDZAMUYMOJTA-UHFFFAOYSA-N 0.000 description 1
FDFQRDWUCVUNBS-UHFFFAOYSA-N 8-[(5-nitro-1,2-diaza-4-azanidacyclopenta-2,5-dien-3-yl)sulfonyl]quinoline Chemical compound N1=CC=CC2=CC=CC(=C12)S(=O)(=O)C1=N[C-](N=N1)[N+](=O)[O-] FDFQRDWUCVUNBS-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Chemical group COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Chemical group CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
BPPSXUMYFPFFGX-OJBOMGDHSA-N C(C1=CC=CC=C1)(=O)NC=1C=2N=CN([C@H]3[C@](O)([C@H](O)[C@@H](C(O)[SiH3])O3)[SiH3])C2N=CN1 Chemical compound C(C1=CC=CC=C1)(=O)NC=1C=2N=CN([C@H]3[C@](O)([C@H](O)[C@@H](C(O)[SiH3])O3)[SiH3])C2N=CN1 BPPSXUMYFPFFGX-OJBOMGDHSA-N 0.000 description 1
WHHCNPRYWYDAEC-SDBHATRESA-N C(CCCC)O[C@H]1[C@H]([C@@H](O[C@@H]1CO)N1C=NC=2C(N)=NC=NC1=2)O Chemical compound C(CCCC)O[C@H]1[C@H]([C@@H](O[C@@H]1CO)N1C=NC=2C(N)=NC=NC1=2)O WHHCNPRYWYDAEC-SDBHATRESA-N 0.000 description 1
KMOPDJQXFCSAEC-XNIJJKJLSA-N C(CCCCC)O[C@H]1[C@H]([C@@H](O[C@@H]1CO)N1C=NC=2C(N)=NC=NC1=2)O Chemical compound C(CCCCC)O[C@H]1[C@H]([C@@H](O[C@@H]1CO)N1C=NC=2C(N)=NC=NC1=2)O KMOPDJQXFCSAEC-XNIJJKJLSA-N 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
241001342895 Chorus Species 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
241000713310 Human T-cell lymphotropic virus type 4 Species 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
241001135958 Human type D retrovirus Species 0.000 description 1
GRSZFWQUAKGDAV-KQYNXXCUSA-L IMP(2-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-L 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
ACIMRXKJKQGBGL-UHFFFAOYSA-N N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NCCN)=CC=CC2=C1Cl ACIMRXKJKQGBGL-UHFFFAOYSA-N 0.000 description 1
GYMWSBVKAPVTPI-UHFFFAOYSA-N N1N=[C-]N=C1 Chemical compound N1N=[C-]N=C1 GYMWSBVKAPVTPI-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229910003873 O—P—O Inorganic materials 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
235000010582 Pisum sativum Nutrition 0.000 description 1
240000004713 Pisum sativum Species 0.000 description 1
102100040153 Poly(A) polymerase gamma Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
NIGBBYOWCRTFNY-DMEFTLKTSA-N [6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-phenylmethanone Chemical compound C(C1=CC=CC=C1)(=O)C=1N=C(C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N1)N NIGBBYOWCRTFNY-DMEFTLKTSA-N 0.000 description 1
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
BVVCDLLKIBUISQ-UHFFFAOYSA-N acetonitrile;pyridine Chemical compound CC#N.C1=CC=NC=C1 BVVCDLLKIBUISQ-UHFFFAOYSA-N 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
210000003323 beak Anatomy 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
229940125844 compound 46 Drugs 0.000 description 1
229940127271 compound 49 Drugs 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
HAORKNGNJCEJBX-UHFFFAOYSA-N cyprodinil Chemical compound N=1C(C)=CC(C2CC2)=NC=1NC1=CC=CC=C1 HAORKNGNJCEJBX-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000005828 desilylation reaction Methods 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000002360 explosive Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Chemical group C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
210000001739 intranuclear inclusion body Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000005497 microtitration Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
HCYLDPYGDUHHKM-YNCYVDIXSA-N n-[9-[(2r,3r,4r,5r)-4-hydroxy-3-trityloxy-5-(trityloxymethyl)oxolan-2-yl]purin-6-yl]benzamide Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C2=NC=NC(NC(=O)C=3C=CC=CC=3)=C2N=C1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)O)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 HCYLDPYGDUHHKM-YNCYVDIXSA-N 0.000 description 1
NZDWTKFDAUOODA-CNEMSGBDSA-N n-[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]benzamide Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC(=O)C=3C=CC=CC=3)=C2N=C1 NZDWTKFDAUOODA-CNEMSGBDSA-N 0.000 description 1
GNPRDDYSJSKPJF-XWCIJXRUSA-N n-[9-[(2r,3r,5s)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]benzamide Chemical compound O1[C@H](CO)C[C@@H](O)[C@@H]1N1C2=NC=NC(NC(=O)C=3C=CC=CC=3)=C2N=C1 GNPRDDYSJSKPJF-XWCIJXRUSA-N 0.000 description 1
AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
230000018791 negative regulation of catalytic activity Effects 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
231100000028 nontoxic concentration Toxicity 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
WRMXOVHLRUVREB-UHFFFAOYSA-N phosphono phosphate;tributylazanium Chemical compound OP(O)(=O)OP([O-])([O-])=O.CCCC[NH+](CCCC)CCCC.CCCC[NH+](CCCC)CCCC WRMXOVHLRUVREB-UHFFFAOYSA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940070891 pyridium Drugs 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000002976 reverse transcriptase assay Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
238000007070 tosylation reaction Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical class CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Botany (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

DK199002913A 1988-06-09 1990-12-07 Anvendelse af visse 2',5'-oligoadenylatanaloger til fremstilling af et lægemiddel mod retrovirusinfektioner, hidtil ukendte blandt en sådan type forbindelser, også til anvendelse ved behandling af en retrovirusinfektion, samt anvendelse af ........ DK174025B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US20465988A	1988-06-09	1988-06-09
US20465988		1988-06-09
PCT/US1989/002284 WO1989012380A2 (en)	1988-06-09	1989-05-24	Therapeutic uses of 2',5'-oligoadenylate derivatives
US8902284		1989-05-24

Publications (3)

Publication Number	Publication Date
DK291390A DK291390A (da)	1990-12-07
DK291390D0 DK291390D0 (da)	1990-12-07
DK174025B1 true DK174025B1 (da)	2002-04-29

Family

ID=22758878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK199002913A DK174025B1 (da)	1988-06-09	1990-12-07	Anvendelse af visse 2',5'-oligoadenylatanaloger til fremstilling af et lægemiddel mod retrovirusinfektioner, hidtil ukendte blandt en sådan type forbindelser, også til anvendelse ved behandling af en retrovirusinfektion, samt anvendelse af ........

Country Status (14)

Country	Link
EP (2)	EP0420872B1 (pt)
JP (1)	JP2947580B2 (pt)
KR (1)	KR0141684B1 (pt)
CN (1)	CN1107508C (pt)
AT (2)	ATE141796T1 (pt)
AU (1)	AU637975B2 (pt)
CA (1)	CA1335356C (pt)
DE (2)	DE68927055T2 (pt)
DK (1)	DK174025B1 (pt)
ES (1)	ES2016464A6 (pt)
IL (1)	IL90499A (pt)
NZ (1)	NZ229422A (pt)
PT (1)	PT90816B (pt)
WO (1)	WO1989012380A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5550111A (en) *	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
IE882585L (en) *	1988-08-25	1990-02-25	Prendergast Patrick T	Viral treatment system
PH30703A (en) *	1990-06-21	1997-09-16	Patrick T Prendergast	Administering particular compounds against variousparasites, mycoplasmas, other indications and otheer indications and other infections.
US5594121A (en) *	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
EP0695306A1 (en) *	1993-04-19	1996-02-07	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
AU7804798A (en)	1997-06-12	1998-12-30	Temple University - Of The Commonwealth System Of Higher Education	Base-modified derivatives of 2',5'-oligoadenylate and antiviral uses thereof
WO1998056384A1 (en)	1997-06-12	1998-12-17	Temple University - Of The Commonwealth System Of Higher Education	Aminoaklanoyl-linked conjugates of 2',5'-oligoadenylate and antiviral uses thereof
AU5429000A (en) *	1999-06-25	2001-01-31	Sankyo Company Limited	Novel bicyclonucleoside derivatives
TWI347948B (en) *	2002-11-19	2011-09-01	Sankyo Co	Novel 2',5'-oligoadenylic acid compositions
GB201019043D0 (en)	2010-11-10	2010-12-22	Protea Biopharma N V	Use of 2',5'-oligoadenylate derivative compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4210746A (en) *	1978-08-10	1980-07-01	National Research Development Corporation	Nucleotide inhibitor of protein synthesis
US4539313A (en) *	1981-04-10	1985-09-03	Research Corporation	(2'-5')-Oligo (3'-deoxyandenylate) and derivatives thereof
US4464359A (en) *	1981-04-10	1984-08-07	Research Corporation	(2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
US4824941A (en) *	1983-03-10	1989-04-25	Julian Gordon	Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4859768A (en) *	1984-07-11	1989-08-22	Temple University Of The Commonwealth System Of Higher Education	Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof
US4654326A (en) *	1984-07-12	1987-03-31	Yair Devash	Inhibition of plant viruses with oligonucleotides

1989
- 1989-05-24 WO PCT/US1989/002284 patent/WO1989012380A2/en active IP Right Grant
- 1989-05-24 AT AT89906575T patent/ATE141796T1/de not_active IP Right Cessation
- 1989-05-24 DE DE68927055T patent/DE68927055T2/de not_active Expired - Fee Related
- 1989-05-24 DE DE68929321T patent/DE68929321T2/de not_active Expired - Fee Related
- 1989-05-24 EP EP89906575A patent/EP0420872B1/en not_active Expired - Lifetime
- 1989-05-24 EP EP96101815A patent/EP0716856B1/en not_active Expired - Lifetime
- 1989-05-24 AU AU37403/89A patent/AU637975B2/en not_active Ceased
- 1989-05-24 KR KR1019900700257A patent/KR0141684B1/ko not_active IP Right Cessation
- 1989-05-24 AT AT96101815T patent/ATE204752T1/de not_active IP Right Cessation
- 1989-05-24 JP JP1506395A patent/JP2947580B2/ja not_active Expired - Fee Related
- 1989-06-01 IL IL9049989A patent/IL90499A/en not_active IP Right Cessation
- 1989-06-08 ES ES8901996A patent/ES2016464A6/es not_active Expired - Lifetime
- 1989-06-09 PT PT90816A patent/PT90816B/pt not_active IP Right Cessation
- 1989-06-09 CA CA000602302A patent/CA1335356C/en not_active Expired - Fee Related
- 1989-06-09 CN CN89106235A patent/CN1107508C/zh not_active Expired - Fee Related
- 1989-10-06 NZ NZ229422A patent/NZ229422A/xx unknown
1990
- 1990-12-07 DK DK199002913A patent/DK174025B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2016464A6 (es)	1990-11-01
EP0716856A2 (en)	1996-06-19
EP0716856B1 (en)	2001-08-29
JPH03504970A (ja)	1991-10-31
WO1989012380A2 (en)	1989-12-28
KR0141684B1 (ko)	1998-06-01
DE68927055T2 (de)	1997-04-10
IL90499A0 (en)	1990-01-18
DK291390A (da)	1990-12-07
NZ229422A (en)	1992-12-23
WO1989012380A3 (en)	1990-06-28
PT90816B (pt)	1994-11-30
ATE204752T1 (de)	2001-09-15
JP2947580B2 (ja)	1999-09-13
AU3740389A (en)	1990-01-12
EP0420872A4 (en)	1992-10-21
DE68929321D1 (de)	2001-10-04
EP0420872A1 (en)	1991-04-10
IL90499A (en)	1994-05-30
DE68929321T2 (de)	2002-05-08
EP0420872B1 (en)	1996-08-28
CN1040321A (zh)	1990-03-14
CA1335356C (en)	1995-04-25
KR900701279A (ko)	1990-12-01
DK291390D0 (da)	1990-12-07
ATE141796T1 (de)	1996-09-15
EP0716856A3 (en)	1996-10-30
CN1107508C (zh)	2003-05-07
PT90816A (pt)	1989-12-29
DE68927055D1 (de)	1996-10-02
AU637975B2 (en)	1993-06-17

Publication	Publication Date	Title
US5643889A (en)	1997-07-01	Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US5550111A (en)	1996-08-27	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
CA1336820C (en)	1995-08-29	Fluorinated nucleosides and process for treating retrovirus infections therewith
EP0570514A1 (en)	1993-11-24	Methylene phosphonate nucleoside analogs and oligonucleotide analogs made therefrom
DK174025B1 (da)	2002-04-29	Anvendelse af visse 2',5'-oligoadenylatanaloger til fremstilling af et lægemiddel mod retrovirusinfektioner, hidtil ukendte blandt en sådan type forbindelser, også til anvendelse ved behandling af en retrovirusinfektion, samt anvendelse af ........
US5700785A (en)	1997-12-23	3'-deoxy or 3'-O-substituted-2',5'-oligoadenylates as antiviral agents
WO1998056385A1 (en)	1998-12-17	Base-modified derivatives of 2',5'-oligoadenylate and antiviral uses thereof
EP0777485B1 (en)	2003-02-19	2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof
EP0739899B1 (en)	2001-06-13	Novel oligoribonucleotide derivatives and application thereof to antiviral agents
US5153180A (en)	1992-10-06	Fluorinated nucleosides and process for treating retrovirus infections therewith
EP0630249B1 (en)	2002-09-18	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
NZ240169A (en)	1997-06-24	The use of 2',5'-olioadenylates to treat virus infections
IL106709A (en)	1996-11-14	Antiviral preparations containing viruses containing 2,5-oligoadnylates
US6130324A (en)	2000-10-10	Amphipathic oligonucleotides and polynucleotides having potent antiviral activity
US6319711B1 (en)	2001-11-20	Composition and method for inhibiting reverse transcript of a retrovirus
IE83348B1 (en)	2004-03-10	Therapeutic uses of 2',5'-oligoadenylate derivatives
Sarin et al.	1992	Use of Drugs Targeted to Inhibit Different Stages of the HIV Life Cycle in the Treatment of AIDS

Legal Events

Date	Code	Title	Description
2002-04-29	B1	Patent granted (law 1993)
2004-05-03	PBP	Patent lapsed	Country of ref document: DK